Free press releases distribution network?

More news: Research
Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Research of Patients and Physicians About Drug Delivery Technologies in the U.S. Produces Exciting New Study - Recent patient and physician research conducted by Frost & Sullivan's Pharmaceutical/Biotechnology Group generates a new end user study on the preferences and drivers of adoption for various drug delivery technologies in the U.S. pharmaceutical market
Research of Patients and Physicians About Drug Delivery Technologies in the U.S. Produces Exciting New Study

 

PRZOOM - /newswire/ - Palo Alto, CA, United States, 2008/03/04 - Recent patient and physician research conducted by Frost & Sullivan's Pharmaceutical/Biotechnology Group generates a new end user study on the preferences and drivers of adoption for various drug delivery technologies in the U.S. pharmaceutical market.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Through more than 200 detailed interviews with a variety of physician specialties such as Primary Care Physicians, Endocrinologists, Rheumatologists and Neurologists, as well as 450 patient interviews, research analysts identified key drivers and obstacles to adoption and utilization of various drug delivery technologies. Disease areas of focus for this research are diabetes, chronic pain, inflammatory diseases, and neurological disorders.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of this latest analysis of the U.S Drug Delivery Markets, or sample slides of this study then send an email to Melina Trevino - Corporate Communications at melina.trevino[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state, and country. We will send you the information via email upon receipt of the above information.

"Understanding the views and desires of patients and physicians about drug delivery technologies is an important asset to drug developers," notes Frost & Sullivan Industry Manager, Daniel Ruppar. "As pharmaceutical and biotechnology companies seek to develop the medicines of the future, finding congruency with both patients and prescribers can make the difference between product success and failure. In the wake of the failure of the first inhaled insulin, this research reveals potential insight into areas of opportunity and high desire to end-users."

How important is ease of self-administration to patients? Understanding this question as well as points such as what is valued, willingness to try new technologies, and factors that may deter usage are key points of analysis that can aid companies throughout the drug development and marketing paradigm. In addition, this research analyzes patient responses for several specific products including Byetta, Exubera, Enbrel, Humira and Voltaren Gel, detailing factors such as awareness, usage, and desired product changes. Respondents also present feedback on usage and future adoption of auto-injectors.

"As companies seek product opportunities, an understanding of patient and physician views of drug delivery factors could influence portfolio and development decisions," explains Daniel Ruppar. "Additionally, understanding issues such as patient cost/copay and how value is important for developers."

"Manufacturers that can better understand the drivers and obstacles of adoption and utilization preferences for pharmaceutical drug delivery can develop and refine their technologies to best serve customer demand," says Ruppar. "The identification of technologies of high interest to clinicians and patients by disease area could lead to breakthrough products for developers."

The drug delivery market, valued at over $55.0 billion in 2006 is poised to undergo rapid expansion owing to major patent expiries, generic competition, increasing focus on life cycle management and tightening FDA regulations. Drug delivery technology companies enable drug companies to expand the product development options available to them. As a result, drug delivery companies expect to remain a focus point for developer companies including: pharmaceutical, biotechnology and specialty pharmaceutical companies.

U.S. Drug Delivery: Usage Patterns, Preferences and Opportunities in the U.S. is part of ongoing research conducted within the Pharmaceutical and Biotechnology subscription, which also includes research in the following markets: Contract Research and Manufacturing, Specialty Pharmaceuticals, Biopharmaceuticals, Vaccines, and Drug Delivery. Recent titles include: U.S. Biotechnology: Monoclonal Antibodies Market, Global CRO Spending Trends, and U.S. Specialty Pharmaceuticals – Overview and Trends. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Analyst Interviews are available to the press.

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


Research of Patients and Physicians About Drug Delivery Technologies in the U.S. Produces Exciting New Study

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Melina Trevino 
210.247.2440 melina.trevino[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Research Most Recent Related Press Releases:

DSM Brings Digestive Comfort to Gluten Sensitive Adults with Launch of Unique Enzyme
DSM Announces Exclusive Partnership with Nanjing Cosmos Chemical Co., Ltd and Plans to Continue Expansion in UV Filters
DSM Launches New Enzyme Solutions At IFT17 to Improve Softness and Moistness of Gluten-free Bread
DSM and Evonik Select Nebraska for Production of Breakthrough Omega-3
Phasor to Develop Next Generation Electronically Steerable Antenna Featuring DSM Dyneema’s Advanced Radome Solution
DSM’s Delvotest® T Antibiotic Residue Test for Milk Validated by Finnish Food Safety Authority
Royal DSM to Make Equity Investment in Amyris with the Purpose of Establishing A Long-term Relationship
DSM Unveils New Beauty Active At NYSCC Suppliers’ Day
Iridea Bio - A New Sustainable Paint Made with DSM’s Decovery® Plant-based Resin
DSM to Showcase A Wide Range of Innovative Composite Solutions

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  S&A Capital Partner Ltd

Visit  RightITnow Ltd

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today